Published Online: Friday, June 1, 2007
<p>Joseph L. Fink III, BSPharm, JD, recently received the University of Kentucky&rsquo;s (UK) President&rsquo;s Award for Diversity. The award was established to honor individuals who have demonstrated outstanding efforts toward advancing the university&rsquo;s mission of embracing diversity while maintaining academic excellence.</p>
<p>Dr. Fink, professor of pharmacy law and policy, was recognized for his innovation and leadership primarily while serving as associate vice chancellor for academic affairs at the university from 1988 to1996, as well as for his work while associate vice president for research. In those 2 roles, Dr. Fink accomplished the following: </p>
  <li>He implemented detailed personal review of applicants&rsquo; files for admission to ensure that full information about applicants of all backgrounds was taken into account, leading to increased admission of both black students and students from Appa-lachian counties</li>
  <li>He conceived the &ldquo;Come See for Yourself&rdquo; minority high school student recruitment initiative designed to overcome the resistance to UK that high school students were getting from relatives and friends because of UK&rsquo;s past racial segregation</li>
  <li>He created weekly staff and monthly meetings of all UK staff members campus-wide working in admission-related activities to ensure that institutional goals in the area of academic quality and diversity of the student body were met and exceeded <br>
<p>As a result of these efforts, the UK had record enrollments of black students.</p>
<p><em>For Dr. Fink&rsquo;s Pharmacy Law column, see page 112.</em></p>

Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues